Richard W. Swanson (1996). Family Practice Review: A Problem Oriented Approach. Mosby, 313. ISBN 978-0-8151-8624-3 "Until very recently, the "gold standard" of pharmacologic therapy for obsessive-compulsive disorder has been clomipramine. At this time, however, the SSRIs (selective serotonin reuptake inhibitors) have become the drugs of choice."
(november 2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology22 (6): 323–9. PMID17917550. DOI: 10.1097/YIC.0b013e3282eff7e0.
(oktober 1997). Clomipramine treatment of panic disorder: pros and cons. The Journal of Clinical Psychiatry58 (10): 423–5. PMID9375591. DOI: 10.4088/JCP.v58n1002.
Nilsson, HL (1989). Review. Clomipramine in acute and chronic pain syndromes. Nordic Journal of Psychiatry43 (s20): 101–113. DOI: 10.3109/08039488909100841.
(januari 2016). Tricyclic and related drugs for nocturnal enuresis in children. The Cochrane Database of Systematic Reviews (1): CD002117. PMID26789925. DOI: 10.1002/14651858.CD002117.pub2.
(augustus 2011). Trichotillomania and its treatment: a review and recommendations. Expert Review of Neurotherapeutics11 (8): 1165–74. PMID21797657. PMC3190970. DOI: 10.1586/ern.11.93.
(januari 1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Archives of General Psychiatry52 (1): 53–60. PMID7811162. DOI: 10.1001/archpsyc.1995.03950130053006.
(december 2008). Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. Journal of Medical Toxicology4 (4): 238–50. PMID19031375. PMC3550116. DOI: 10.1007/BF03161207.
(mei 2010). Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. The British Journal of Psychiatry196 (5): 354–8. PMID20435959. PMC2862059. DOI: 10.1192/bjp.bp.109.070219.
(december 1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology340 (2–3): 249–58. PMID9537821. DOI: 10.1016/S0014-2999(97)01393-9.
(april 2003). High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Archives of General Psychiatry60 (4): 386–91. PMID12695316. DOI: 10.1001/archpsyc.60.4.386.
(juli 2011). NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. Psychopharmacology216 (2): 279–86. PMID21336575. DOI: 10.1007/s00213-011-2212-9.
(november 2016). Serotonin syndrome: Preventing, recognizing, and treating it. Cleveland Clinic Journal of Medicine83 (11): 810–817. PMID27824534. DOI: 10.3949/ccjm.83a.15129.
(september 2011). Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry44 (6): 236–48. PMID21959785. DOI: 10.1055/s-0031-1286282.
(mei 2009). Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. International Clinical Psychopharmacology24 (3): 119–25. PMID19367152. DOI: 10.1097/YIC.0b013e32832a8ec8.
(1994). Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry33 (6): 792–4. PMID8083135. DOI: 10.1097/00004583-199407000-00003.
(augustus 1991). Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biological Psychiatry30 (3): 225–32. PMID1832972. DOI: 10.1016/0006-3223(91)90107-w.
(april 2013). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. The International Journal of Neuropsychopharmacology16 (3): 557–74. PMID22932229. DOI: 10.1017/S1461145712000740.
(april 2007). An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy8 (5): 563–83. PMID17376013. DOI: 10.1517/14656566.8.5.563.
(juli 2009). Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chemical Communications (25): 3677–92. PMID19557250. DOI: 10.1039/b903035m.
(mei 1998). Use of clomipramine in the treatment of anxiety-related and obsessive-compulsive disorders in cats. Australian Veterinary Journal76 (5): 317–21. PMID9631696. DOI: 10.1111/j.1751-0813.1998.tb12353.x.
(april 2001). Use of clomipramine in treatment of obsessive-compulsive disorder, separation anxiety and noise phobia in dogs: a preliminary, clinical study. Australian Veterinary Journal79 (4): 252–6. PMID11349411. DOI: 10.1111/j.1751-0813.2001.tb11976.x.
(september 2004). Determination of the dosage of clomipramine for the treatment of urine spraying in cats. Journal of the American Veterinary Medical Association225 (6): 881–7. PMID15485047. DOI: 10.2460/javma.2004.225.881.
(november 2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology22 (6): 323–9. PMID17917550. DOI: 10.1097/YIC.0b013e3282eff7e0.
(oktober 1997). Clomipramine treatment of panic disorder: pros and cons. The Journal of Clinical Psychiatry58 (10): 423–5. PMID9375591. DOI: 10.4088/JCP.v58n1002.
(januari 2016). Tricyclic and related drugs for nocturnal enuresis in children. The Cochrane Database of Systematic Reviews (1): CD002117. PMID26789925. DOI: 10.1002/14651858.CD002117.pub2.
(augustus 2011). Trichotillomania and its treatment: a review and recommendations. Expert Review of Neurotherapeutics11 (8): 1165–74. PMID21797657. PMC3190970. DOI: 10.1586/ern.11.93.
(januari 1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Archives of General Psychiatry52 (1): 53–60. PMID7811162. DOI: 10.1001/archpsyc.1995.03950130053006.
(december 2008). Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. Journal of Medical Toxicology4 (4): 238–50. PMID19031375. PMC3550116. DOI: 10.1007/BF03161207.
(mei 2010). Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. The British Journal of Psychiatry196 (5): 354–8. PMID20435959. PMC2862059. DOI: 10.1192/bjp.bp.109.070219.
(december 1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology340 (2–3): 249–58. PMID9537821. DOI: 10.1016/S0014-2999(97)01393-9.
(augustus 2001). S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. The Journal of Pharmacology and Experimental Therapeutics298 (2): 565–80. PMID11454918.
(april 2003). High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Archives of General Psychiatry60 (4): 386–91. PMID12695316. DOI: 10.1001/archpsyc.60.4.386.
(juli 2011). NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. Psychopharmacology216 (2): 279–86. PMID21336575. DOI: 10.1007/s00213-011-2212-9.
(september 2011). Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry44 (6): 236–48. PMID21959785. DOI: 10.1055/s-0031-1286282.
(mei 2009). Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. International Clinical Psychopharmacology24 (3): 119–25. PMID19367152. DOI: 10.1097/YIC.0b013e32832a8ec8.
(1994). Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry33 (6): 792–4. PMID8083135. DOI: 10.1097/00004583-199407000-00003.
(augustus 1991). Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biological Psychiatry30 (3): 225–32. PMID1832972. DOI: 10.1016/0006-3223(91)90107-w.
(april 2013). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. The International Journal of Neuropsychopharmacology16 (3): 557–74. PMID22932229. DOI: 10.1017/S1461145712000740.
(april 2007). An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy8 (5): 563–83. PMID17376013. DOI: 10.1517/14656566.8.5.563.
(juli 2009). Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chemical Communications (25): 3677–92. PMID19557250. DOI: 10.1039/b903035m.
(mei 1998). Use of clomipramine in the treatment of anxiety-related and obsessive-compulsive disorders in cats. Australian Veterinary Journal76 (5): 317–21. PMID9631696. DOI: 10.1111/j.1751-0813.1998.tb12353.x.
(april 2001). Use of clomipramine in treatment of obsessive-compulsive disorder, separation anxiety and noise phobia in dogs: a preliminary, clinical study. Australian Veterinary Journal79 (4): 252–6. PMID11349411. DOI: 10.1111/j.1751-0813.2001.tb11976.x.
(september 2004). Determination of the dosage of clomipramine for the treatment of urine spraying in cats. Journal of the American Veterinary Medical Association225 (6): 881–7. PMID15485047. DOI: 10.2460/javma.2004.225.881.
ANAFRANIL (clomipramine) (PDF). TGA eBusiness Services. NOVARTIS Pharmaceuticals Australia Pty Limited (7 december 2012). Gearchiveerd op 12 augustus 2017. Geraadpleegd op 30 november 2013.
ANAFRANIL (clomipramine) (PDF). TGA eBusiness Services. NOVARTIS Pharmaceuticals Australia Pty Limited (7 december 2012). Gearchiveerd op 12 augustus 2017. Geraadpleegd op 30 november 2013.